openPR Logo
Press release

Acute Lymphoblastic Leukemia Therapeutics Market Share and Future Growth to 2026 | SWOT Analysis by Players Novartis Pharmaceuticals, Pfizer Inc., Genzyme Corporation, GlaxoSmithKline Plc., Biogen Idec, Inc., ERYTECH Pharma, Bristol-Myers Squibb

05-20-2019 03:28 PM CET | Health & Medicine

Press release from: Coherent Market Insights

Acute Lymphoblastic Leukemia Therapeutics

Acute Lymphoblastic Leukemia Therapeutics

Acute lymphoblastic leukemia (ALL) is a type of cancer affecting the bone marrow and blood. The condition is characterized by overproduction of immature white blood cells, also known as lymphoblast. The immature or abnormal cells are unable to function properly and build up around the healthy cells. Patients diagnosed with ALL are highly susceptible to recurrent infections, anemia, bleeding and bruising easily as the bone marrow is unable to form adequate numbers of red blood cells, white blood cells, and platelets. The cancer is characterized with high progression rate, and can be fatal if not treated within few months. The cancerous cells have the potential to spread to other organs of the body including lymph nodes, liver, spleen, and the central nervous system. The common symptoms of the condition include renal failure, pneumonia, respiratory distress, and bone pain. Acute lymphocytic leukemia is the most common type of cancer in children, where timely treatment and diagnosis results in efficient cure of the condition.

Ask for Sample Copy of Acute Lymphoblastic Leukemia Therapeutics Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/1606

Market Dynamics

Increasing incidence of acute lymphoblastic leukemia coupled with rising association of the disease with genetic disorders such as Down syndrome in children is a major factor augmenting the market growth. According to the Healthline Media UK Ltd., 2017, ALL accounts for 80% of childhood leukemia and is the most common type of cancer and leukemia in children under 5 years of age than in adults, mostly affecting children aged 2 to 3 years. Also, according to survey by MedicineNet, a medical information portral, about two-thirds of acute leukemia diagnosed in children are associated with Down syndrome, thus increasing the likelihood of children affected with genetic disorders to develop ALL. Furthermore, factors such as high exposure to toxins- benzene and radiations such as X-rays before birth are expected to increase risk of developing ALL and this is expected to propel demand for treatment of the disease using various therapeutics. Therefore, this is expected to aid in growth of the market.

Regional Dynamics

Regional segmentation of the global acute lymphoblastic leukemia therapeutics market by Coherent Market Insights comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global acute lymphoblastic leukemia therapeutics market over the forecast period, owing to rising prevalence of the disease and rising number of clinical trials undertaken by organizations in the region to address the unmet medical needs of patients. According to the American Cancer Society, 2016, an estimated 5,970 new ALL diagnoses and 1,440 deaths from ALL were registered in 2017. Also, according to the St. Jude Children’s Research Hospital, about 3,000 people aged below 20 years are found to have acute lymphoblastic leukemia each year in the U.S.

Competitive Analysis

Key players operating in the global acute lymphoblastic leukemia therapeutics market include Novartis Pharmaceuticals, Pfizer Inc., Genzyme Corporation, GlaxoSmithKline Plc., ERYTECH Pharma, Talon Therapeutic, Inc., Sigma-Tau Pharmaceuticals, Inc., Spectrum Pharmaceuticals, Inc. F. Hoffmann-La Roche Ltd., Biogen Idec, Inc., Bristol-Myers Squibb, and Celgene Corporation.

Market Taxonomy

On the basis of drug type, global acute lymphoblastic leukemia therapeutics market is segmented into:

Chemotherapy Drugs
- Nelarabine (Arranon)
- Blinatumomab (Blincyto)
- Clofarabine (Clolar)
- Erwinia (Erwinase)
- Pegaspargase (Oncaspar)
- Vincristine (Marqibo)
- Others
Immunotherapy Drugs
- Tisagenlecleucel (Kymriah)
- Targeted Therapy Drugs
- Imatinib (Gleevec)
- Dasatinib (Sprycel)
- Nilotinib (Tasigna)
- Others
Others

On the basis of indication, global acute lymphoblastic leukemia therapeutics market is segmented into:

Precursor B Cell ALL
Mature B Cell ALL
Precursor T Cell ALL

Request For Customization of Acute Lymphoblastic Leukemia Therapeutics Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/1606

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Acute Lymphoblastic Leukemia Therapeutics Market Share and Future Growth to 2026 | SWOT Analysis by Players Novartis Pharmaceuticals, Pfizer Inc., Genzyme Corporation, GlaxoSmithKline Plc., Biogen Idec, Inc., ERYTECH Pharma, Bristol-Myers Squibb here

News-ID: 1745824 • Views:

More Releases from Coherent Market Insights

Healthcare Staffing Market See Incredible Growth 2025-2032 | LocumTenens.com, Adecco Group, TeamHealth, Trustaff
Healthcare Staffing Market See Incredible Growth 2025-2032 | LocumTenens.com, Ad …
Healthcare Staffing Market is estimated to be valued at USD 45.75 Bn in 2025 and is expected to reach USD 76.4 Bn in 2032, exhibiting a compound annual growth rate (CAGR) of7.6% from 2025 to 2032. The latest report from Coherent Market Insights examines the growth prospects of the Healthcare Staffing Market from 2025 to 2032. This in-depth analysis covers industry size, market share, business trends, key growth factors, and
Microdermabrasion Devices Market Set to Witness Significant Growth by 2025-2032 | DermaSweep Inc., Lifetrons Switzerland AG, Trophy Skin, Silk'n
Microdermabrasion Devices Market Set to Witness Significant Growth by 2025-2032 …
Microdermabrasion devices market is estimated to be valued at USD 604.2 Mn in 2025 and is expected to reach USD 1,035.5 Mn in 2032, exhibiting a compound annual growth rate (CAGR) of8% from 2025 to 2032. The latest report from Coherent Market Insights examines the growth prospects of the Microdermabrasion Devices Market from 2025 to 2032. This in-depth analysis covers industry size, market share, business trends, key growth factors, and regional
Rising Trends of Digestive Drugs Market Future Business Opportunities 2025-2032 | GlaxoSmithKline plc, AbbVie Inc. (Allergan), Takeda Pharmaceutical Company Limited, Pfizer Inc
Rising Trends of Digestive Drugs Market Future Business Opportunities 2025-2032 …
Digestive Drugs Market is estimated to be valued at USD 62,393.7 Mn in 2025 and is expected to reach USD 92,953.1 Mn in 2032, exhibiting a compound annual growth rate (CAGR) of 5.86% from 2025 to 2032. The latest report from Coherent Market Insights examines the growth prospects of the Digestive Drugs Market from 2025 to 2032. This in-depth analysis covers industry size, market share, business trends, key growth factors, and
Bioceramics Market Set for Significant Growth by 2025 - Comprehensive Competitive Landscape Through 2032 | CoorsTek, Inc., Kyocera Corporation, Morgan Advanced Materials
Bioceramics Market Set for Significant Growth by 2025 - Comprehensive Competitiv …
Bioceramics market is estimated to be valued at USD 4,757.5 Mn in 2025 and is expected to reach USD 6,409.5 Mn in 2032, exhibiting a compound annual growth rate (CAGR) of4.35% from 2025 to 2032. The latest report from Coherent Market Insights examines the growth prospects of the Bioceramics Market from 2025 to 2032. This in-depth analysis covers industry size, market share, business trends, key growth factors, and regional forecasts. The

All 5 Releases


More Releases for Acute

Acute Lymphoblastic Leukemia Therapeutics Market Size, Acute Lymphoblastic Leuke …
Acute Lymphoblastic Leukemia Therapeutics Market Dynamics are clarified by an in-depth review of facts on current and emerging trends. To understand a resource, the paper uses Porter's five forces to examine the importance of numerous qualities such as understanding of suppliers and customers, dangers provided by various agents, competitive strength, and promising new businesses. precious. Furthermore, the study covers numerous firms' Acute Lymphoblastic Leukemia Therapeutics research data, benefit, gross margin,
Acute Conjunctivitis Treatment Market: The Future Insights Of Global Acute Conju …
Acute Conjunctivitis Treatment Market Acute Conjunctivitis Treatment Market, or pink eye, is an irritation or inflammation of the conjunctiva that covers the white part of the eyeball. It can be caused by allergies or a bacterial or viral infection. Acute Conjunctivitis Treatment Market can be highly communicable and can be spread easily by the contact with secretions of eye from the infected person. Conjunctivitis often resolves on its own, but
Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H …
ReportsWorldwide has announced the addition of a new report title Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports. GlobalData's clinical trial report, “Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Renal Failure (ARF) (Acute Kidney Injury) clinical trials scenario. This report provides top line data relating to
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical T …
ReportsWorldwide has announced the addition of a new report title Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports. GlobalData's clinical trial report, “Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trials scenario. This report provides top line data relating to
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Tri …
ReportsWorldwide has announced the addition of a new report title Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports. GlobalData's clinical trial report, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) clinical trials scenario. This report provides top line data relating to
H2 2016 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeut …
Albany, New York, January 03, 2017: A recent forecast report focusing on the Acute Myelocytic Leukemia Market has been added to the wide portfolio of Market Research Hub (MRH). It is entitled as, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2016” which has been equipped by in-depth market examination with inputs from the industry experts. It covers the current market scenario and also its future growth